Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405Status:In development | In consultationProgramme:Health technology evaluationConsultation end date: 23 May 2024Expected publication date: TBC